Cash Flow Statement (Annual)

AMD / Advanced Micro Devices, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss - 471,000 491,000 -1,183,000 -83,000 -403,000 -660,000 -497,000 43,000
  Profit Loss 293,000 471,000 491,000 - - - - - -
  Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Related Party Noncash Transaction - 0 0 278,000 0 0 - - -
    Income Loss From Equity Method Investments - -462,000 492,000 0 0 0 0 -10,000 -7,000
    Depreciation And Amortization 1,128,000 383,000 317,000 260,000 236,000 203,000 - - -
    Deferred Income Tax Expense Benefit 128,000 -5,000 -6,000 -40,000 1,000 0 -1,000 20,000 -16,000
    Share Based Compensation 75,000 87,000 90,000 97,000 91,000 81,000 63,000 86,000 97,000
    Amortization Of Financing Costs And Discounts 121,000 30,000 21,000 23,000 25,000 17,000 11,000 21,000 36,000
    Other Noncash Income Expense 44,000 27,000 3,000 -7,000 1,000 13,000 3,000 8,000 -3,000
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable 960,000 1,138,000 347,000 -290,000 200,000 -7,000 -280,000 -222,000 89,000
    Increase Decrease In Inventories -89,000 144,000 -157,000 83,000 322,000 -199,000 11,000 73,000 -12,000
    Increase Decrease In Prepaid Deferred Expense And Other Assets - 97,000 -115,000 20,000 11,000 7,000 111,000 166,000 140,000
    Increase Decreasein Prepayments Related Parties - - - 0 0 113,000 -84,000 -1,000 1,000
    Increase Decrease In Prepaid Expense And Other Current Assets 17,000 97,000 -115,000 - - - - - -
    Increase Decrease In Other Operating Assets 18,000 -11,000 1,000 12,000 92,000 - - - -
    Increase Decrease In Accounts Payable Related Parties - 55,000 -28,000 277,000 -89,000 -146,000 27,000 128,000 29,000
    Increase Decrease In Due To Related Parties Current - - - - - -146,000 27,000 10,000 -
    Increase Decrease In Accounts Payable And Accrued Liabilities -133,000 -182,000 -148,000 -232,000 266,000 -231,000 -156,000 58,000 -75,000
  Net Cash Provided By Used In Operating Activities 473,000 -412,000 382,000 -338,000 -148,000 -98,000 -226,000 90,000 68,000
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
  Depreciation Depletion And Amortization - - - - 236,000 203,000 167,000 133,000 144,000
  Income Loss From Equity Method Investments Net Of Dividends Or Distributions - - - - - 0 0 -2,000 -
  Deconsolidation Gain Or Loss Amount - 325,000 0 0 - 0 0 146,000 3,000
  Deferred Income Taxes And Tax Credits - - - - - 0 0 11,000 0
  Impairment Of Investments - 0 209,000 0 0 - - - -
  Gain Loss On Sale Of Property Plant Equipment - - 5,000 -1,000 -31,000 0 0 - -
  Goodwill Impairment Loss - - - 0 0 233,000 0 0 -
  Restructuringand Other Special Charges Net Noncash - - - 4,000 0 14,000 83,000 0 0
  Gain Loss On Sale Of Securities Net - 17,000 4,000 0 - - - - -
  Issuance Of Stock And Warrants For Services Or Claims - - - - - 0 0 240,000 0
  Gains Losses On Extinguishment Of Debt 169,000 -24,000 -6,000 0 -1,000 -61,000 0 -68,000 -12,000
Net Cash Provided By Used In Investing Activities
  Proceeds From Divestiture Of Interest In Consolidated Subsidiaries - - - - - 0 0 342,000 1,000
  Payments To Acquire Businesses Net Of Cash Acquired - 0 0 281,000 0 0 - - -
  Payments To Acquire Property Plant And Equipment 466,000 148,000 250,000 133,000 84,000 95,000 96,000 77,000 113,000
  Payments To Acquire Available For Sale Securities 1,486,000 1,800,000 1,586,000 944,000 1,043,000 790,000 227,000 0 222,000
  Cash Divested From Deconsolidation - 904,000 0 0 - - - - -
  Proceeds From Sale And Maturity Of Available For Sale Securities 603,000 1,640,000 1,726,000 1,348,000 1,344,000 873,000 462,000 0 222,000
  Payments For Proceeds From Other Investing Activities -4,000 -19,000 19,000 9,000 0 0 0 -2,000 2,000
  Proceeds From Payments For Trading Securities 14,000 69,000 0 0 - - - - -
  Net Cash Provided By Used In Investing Activities -1,273,000 -1,123,000 -113,000 -19,000 455,000 -12,000 147,000 267,000 -114,000
  Proceeds From Sale Of Property Plant And Equipment - 1,000 16,000 0 238,000 0 8,000 0 0
Net Cash Provided By Used In Financing Activities
  Proceeds From Issuance Of Long Term Debt - 1,520,000 170,000 491,000 0 1,155,000 100,000 782,000 0
  Proceeds From Issuance Of Long Term Debt Net 1,060,000 1,520,000 170,000 - - - - - -
  Proceeds From Repayments Of Lines Of Credit - - - - - 75,000 100,000 -230,000 70,000
  Proceeds From Lines Of Credit - - 0 0 55,000 - - - -
  Proceeds From Government Grant 55,000 19,000 20,000 - - - - - -
  Proceeds From Grantors - 19,000 20,000 23,000 11,000 8,000 - - -
  Proceeds From Issuance Of Common Stock 125,000 15,000 18,000 14,000 3,000 4,000 5,000 667,000 0
  Repayments Of Long Term Debt And Capital Securities 1,820,000 1,074,000 209,000 - 55,000 1,115,000 44,000 1,113,000 110,000
  Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options - - - - - 4,000 5,000 20,000 20,000
  Repayments Of Debt And Capital Lease Obligations - 1,074,000 209,000 489,000 55,000 1,115,000 - - -
  Proceeds From Payments For Other Financing Activities 1,000 4,000 -5,000 -2,000 -1,000 -6,000 -2,000 -4,000 -13,000
  Net Cash Provided By Used In Financing Activities 1,524,000 484,000 -6,000 37,000 13,000 46,000 59,000 122,000 -33,000
Cash And Cash Equivalents Period Increase Decrease 724,000 -1,051,000 263,000 -320,000 320,000 -64,000 -20,000 479,000 -79,000
Cash And Cash Equivalents At Carrying Value - - 869,000 549,000 869,000 805,000 785,000 1,264,000 1,185,000
Supplemental Cash Flow Information
  Cash Paid
  Interest Paid Net 319,000 164,000 152,000 142,000 152,000 138,000 149,000 149,000 88,000
  Income Taxes Paid Net 14,000 12,000 9,000 9,000 9,000 7,000 3,000 20,000 20,000
Cash Flow Noncash Investing And Financing Activities Disclosure
  Capital Expenditures Incurred But Not Yet Paid - - - - - - 0 0 50,000
  Stock Issued1 - - - - - 0 0 8,000 38,000
  Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 - - - - - - 0 0 12,000

Peers - Semiconductors and Related Devices (3674)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 007903107